Select Bibliography

Filter by any of these (after searching):

NCCTG-N05C5

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 2 items

Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5

Wolf, S. L. , Qin, R. , Menon, S. P. , Rowland, K. M., Jr ... - ASCO - J Clin Oncol - 2010

Abstract - Primary - Primary - Symptom Inter - NCCTG-N05C5

Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5

Wolf, Sherry L. , Qin, Rui , Menon, Smitha P. , Rowland, Kendrith M. ... - - J Clin Oncol - 2010

Manuscript - Primary - Primary - Symptom Inter - NCCTG-N05C5